We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Monte Rosa Therapeutics Inc (GLUE) USD0.0001

Sell:$5.44 Buy:$5.45 Change: $0.02 (0.37%)
NASDAQ:0.64%
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
Sell:$5.44
Buy:$5.45
Change: $0.02 (0.37%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
Sell:$5.44
Buy:$5.45
Change: $0.02 (0.37%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs) for patients living with serious diseases in the areas of oncology and autoimmune, and more. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Contact details

Address:
321 Harrison Avenue, Suite 900
BOSTON
02118
United States
Telephone:
+1 (617) 9492643
Website:
https://www.monterosatx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GLUE
ISIN:
US61225M1027
Market cap:
$274.34 million
Shares in issue:
50.15 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Markus Warmuth
    President, Chief Executive Officer, Director
  • Sharon Townson
    Chief Technology Officer
  • Owen Wallace
    Chief Scientific Officer
  • Philip Nickson
    General Counsel
  • John Castle
    Chief Data Scientist
  • Filip Janku
    Chief Medical Officer
  • Jullian Jones
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.